OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathy
BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics announces full enrollment for its Phase 2 clinical trial of OTT166.